Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar referencing RoActemra® (tocilizumab). Avtozma® has been approved for ...

Celltrion's Avtozma, a biosimilar to Actemra, was approved by the European Commission for sale in member states.

South Korean pharmaceutical firm Celltrion announced Monday that Avtozma, a biosimilar of Actemra, has received approval from the European Commission. The approval covers major indications of the ...

Find earnings, economic, stock splits and IPO calendars to track upcoming financial events from Yahoo Finance.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new benzimidazoles acting as serine/threonine-protein kinase SIK inhibitors reported to be useful for the treatment of rheumatoid ...

Patients with predominantly cranial vs isolated extracranial GCA phenotypes present with different patterns of arterial involvement on 18F-FDG PET-CT scans.

Mortality rates among patients with GCA in Spain are similar to that of the general population, with older age and male sex linked to higher mortality.

Age and hypertension are associated with increased risks for cranial ischemic complications in GCA, while anticoagulant therapy may offer protective benefits.

I am a 67-year-old male with generally good vision. I have had a few floaters in my eyes over the years, but they have generally been small ...

A study showed notable differences in bone mineral density between children on steroids and those not on steroids, with 84% ...

Objectives In order to comprehensively investigate the causal relationship between gut microbiota abundance and giant cell arteritis risk and to identify specific beneficial or pathogenic microbe taxa ...

Giant cell arteritis (GCA) is a chronic systemic vasculitis affecting large-sized and medium-sized vessels. Glucocorticoids are currently the mainstay of treatment for GCA and associated large vessel ...